| Literature DB >> 19377085 |
Hélène Choquet1, Christine Cavalcanti-Proença, Cécile Lecoeur, Christian Dina, Stéphane Cauchi, Martine Vaxillaire, Samy Hadjadj, Fritz Horber, Natasha Potoczna, Guillaume Charpentier, Juan Ruiz, Serge Hercberg, Suliya Maimaitiming, Ronan Roussel, Michael Boenhnke, Anne U Jackson, Wolfgang Patsch, Franz Krempler, Benjamin F Voight, David Altshuler, Leif Groop, Gudmar Thorleifsson, Valgerdur Steinthorsdottir, Kari Stefansson, Beverley Balkau, Philippe Froguel, David Meyre.
Abstract
A recent study reported an association between the brain natriuretic peptide (BNP) promoter T-381C polymorphism (rs198389) and protection against type 2 diabetes (T2D). As replication in several studies is mandatory to confirm genetic results, we analyzed the T-381C polymorphism in seven independent case-control cohorts and in 291 T2D-enriched pedigrees totalling 39 557 subjects of European origin. A meta-analysis of the seven case-control studies (n = 39 040) showed a nominal protective effect [odds ratio (OR) = 0.86 (0.79-0.94), P = 0.0006] of the CC genotype on T2D risk, consistent with the previous study. By combining all available data (n = 49 279), we further confirmed a modest contribution of the BNP T-381C polymorphism for protection against T2D [OR = 0.86 (0.80-0.92), P = 1.4 x 10(-5)]. Potential confounders such as gender, age, obesity status or family history were tested in 4335 T2D and 4179 normoglycemic subjects and they had no influence on T2D risk. This study provides further evidence of a modest contribution of the BNP T-381C polymorphism in protection against T2D and illustrates the difficulty of unambiguously proving modest-sized associations even with large sample sizes.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19377085 DOI: 10.1093/hmg/ddp169
Source DB: PubMed Journal: Hum Mol Genet ISSN: 0964-6906 Impact factor: 6.150